Table 1. Clinicopathological details of patients.
| Number of patients | 81 |
| Median follow-up | 53 months |
| Median age | 60 years |
| Median progression-free survival | 21 months |
| Median overall survival | 28 months |
| Tumour | |
| T1 | 41 (50.6%) |
| T2 | 31 (38.3%) |
| T3 | 7 (8.6%) |
| T4 | 2 (2.5%) |
| Node | |
| N0 | 50 (61.7%) |
| N1 | 20 (24.7%) |
| N2 | 7 (8.6%) |
| N3 | 3 (3.7%) |
| Unknown | 1 |
| Metastases | |
| M0 | 81 (100%) |
| M1 | 0 |
| Stage | |
| 1 | 34 (42%) |
| 2 | 30 (37%) |
| 3 | 16 (19.8%) |
| Unknown | 1 |
| Ki67 | |
| Negative (<20%) | 16 (19.8%) |
| Positive (⩾20%) | 63 (77.8%) |
| Unknown | 2 |
| CK5/6 | |
| Negative (<10%) | 37 (45.7%) |
| Positive (⩾10%) | 44 (54.3%) |
| Chemotherapy after surgery | |
| Yes | 55 (67.9%) |
| No | 24 (29.6%) |
| Unknown | 2 |
| Radiotherapy after surgery | |
| Yes | 59 (72.8%) |
| No | 19 (23.5%) |
| Unknown | 3 |
Abbreviation: CK5/6=cytokeratin5/6.